Table 3.
Antiproliferative activity of phytol (1) and its synthesized derivatives against selected cancer cell lines and normal mice fibroblasts.
| Compound | Cell lines/IC50 ± SD (μM) | |||||
|---|---|---|---|---|---|---|
| MV4-11 | A549 | LoVo | LoVo/DX | BALB/3T3 | ||
| IC50 (μM) | IC50 (μM) | IC50 (μM) | IC50 (μM) | IR | IC50 (μM) | |
| Phytol (1) | 51.4 ± 3.6 | 64.1 ± 5.2 | 255.2 ± 46.5 | 70.8 ± 3.9 | 0.28 | 64.5 ± 12.9 |
| (2) | n.a | n.a | n.a | n.a | – | n.a |
| (3) | 39.28 ± 5.9 | 49.5 ± 2.9 | 59.5 ± 1.1 | 55.03 ± 1.5 | 0.92 | 145.1 ± 48.0 |
| (4) | 46.9 ± 11.7 | n.a | n.a | 306.3 ± 136.5 | – | 348.5 ± 27.6 |
| (5) | 52 ± 13.8 | n.a | n.a | 261.3 ± 104.5 | – | 424 ± 140.2 |
| (6) | 48.3 ± 19.6 | 378.4 ± 32.8 | 293.4 ± 33.1 | 187.5 ± 32.7 | 0.64 | 273 ± 16.4 |
| (7) | 110.5 ± 41.6 | n.a | n.a | 236.8 ± 52.9 | - | n.a |
| Cisplatin | 2.88 ± 0.83 | 3.97 ± 1.08 | 5.55 ± 0.12 | 3.45 ± 1.01 | 0.62 | 4.44 ± 2.36 |
| Doxorubicin | - | - | 0.12 ± 0.01 | 6.53 ± 0.93 | – | – |
n.a. no activity in concentration of 5, 25, 125, 625 μM. IC50—compound concentration leading to 50% inhibition of cell proliferation. Data are presented as mean ± standard deviation (SD) calculated using Prolab-3 system based on Cheburator 0.4 software56. IR was calculated according to the formula IR = (IC50 estimated against resistant cell line)/(IC50 estimated against non-resistant cell line); values range: 0 < IR < 2-indicate that the tested compound is able to overcome drug resistance; 2 < IR < 10—defines the moderate ability of the compound to overcome drug resistance; IR > 10—defines no influence on the drug resistance phenomenon.